Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Following Details Surrounding Matthew Perry's Ketamine Use, ASKP3 Releases Statement & Guidelines For Treating Patients with a History of Substance Abuse


News provided by

ASKP3

Aug 28, 2024, 12:00 ET

Share this article

Share toX

Share this article

Share toX


The society, which has 500+ members across a range of professional and medical ketamine practices, explains the reasons Matthew Perry may or may not have been a good candidate for ketamine therapy.

ALTAMONTE SPRINGS, Fla. , Aug. 28, 2024 /PRNewswire-PRWeb/ -- As reports emerge detailing the days leading to Matthew Perry's death, the American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3), the largest society and think tank for ketamine practitioners, feels it is imperative to address the importance of responsibility in offering ketamine treatment, and underscore the Society's safety standards and considerations regarding proper patient selection.

In consideration of the guidelines listed below, there is reason to believe that Matthew Perry may not have been an ideal candidate for ketamine therapy beyond his initial infusions at a Swiss rehab facility, as reported by The New York Times. Not much is known about the experience and background of his ketamine doctors and clinics in Los Angeles, but in order to safely continue ketamine infusions with his history of substance abuse, his treatment plan would needed to have been implemented by someone highly knowledgeable and experienced with ketamine as one part of an overall substance abuse treatment program.

There is reason to believe that Matthew Perry may not have been an ideal candidate for ketamine therapy.

Post this

This statement is not meant to criticize Mr. Perry's team of in-office practitioners, who seemingly treated him within the currently available regulatory guidelines and safety standards. We only mean to underscore how vital it is for the wider community of ketamine practitioners to fortify standards of care for patients with a history of substance abuse.

It is essential to acknowledge that there is a large evidence base of well-conducted research trials from major academic institutions supporting the safety and efficacy of ketamine, including for treating substance abuse. In addition, there is a severe mental health crisis, with rates of depression and suicide skyrocketing in recent years. Up to one-third of patients with depression are considered treatment-resistant. A legitimate need for more effective treatments exists, and it is imperative to balance the risks and benefits of ketamine therapy through clear standards and treatment guardrails so that this treatment can remain safe and accessible to patients who need it.

KEY STRATEGIES TO ASSESS AND MITIGATE AGAINST RISK OF KETAMINE ABUSE

Science and treatment innovation is moving faster than regulation, producing a significant regulatory void and considerable differences in the quality of care and the safety measures being taken in various clinics. Despite its potential in mental health, there is risk of abuse and misuse with ketamine. As such, careful consideration must be given when treating patients with a history of substance abuse.

  • Patient Selection: Carefully selected, with attention to past and present substance abuse.
  • Supervised Administration: A monitored medical setting with regular follow-up appointments to track response.
  • Patient Education: A thorough discussion of treatment alternatives to manage expectations.
  • Team Engagement: A diverse treatment group that includes a psychotherapist.
  • Monitoring: Response, side-effects, and development of craving and desire for the treatment and/or other substances should be documented with potential use of urine toxicology monitoring in some circumstances

A detailed description of our society guidelines for careful and measured consideration when treating patients with a history of substance abuse can be found HERE.

CALLS-TO-ACTION

It is important to emphasize that ketamine is not considered to be physically addictive in the same way as opiates and alcohol, but rather psychologically addictive in some individuals. While craving for the drug in addiction may be notable, overt withdrawal syndromes, like those seen with alcohol, benzodiazepine and opioid dependence, do not occur with ketamine.

Mr. Perry's situation, while not unique, was an outlier as compared to the average mental health patient without the influence and access to resources that can produce such ready access to excessive doses of ketamine. The vast majority of mental health patients will not have the means to access ketamine in such an extreme fashion, but safety looking forward is paramount. Today, the critical issues we must address are those that impact patients in the current evolving care climate, with its historic push towards mental health care innovation occurring outside of classical FDA-approval.

ASKP3 points to actions and solutions that can both ensure safety for the general public, while preserving access to this life-saving therapy, include:

  • Adherence to Standards and Ethics: ASKP3 is engaged in urgent efforts towards developing cohesive community ethics and standards of care, to provide guardrails, appropriate protocols, and comprehensive risk assessment for treatment of mental health disorders, including substance abuse.
  • Insurance coverage for ketamine therapy. ASKP3 calls for development of Prior Authorization Clauses that can help establish payment for off-label ketamine. Insurance reimbursement can help more people seek out in-office, medically-supervised treatment – the safest and most controlled environment for ketamine therapy – rather than unsupervised treatment at home.
  • New FDA approved treatments: ASKP3 supports efforts to establish safety, efficacy and dosing ranges for ketamine and other NMDA receptor antagonists through FDA processes that can complement the large body of research supporting off-label treatments

Media Contact

Teresa Bigelow, ASKP3, 1 6462230402, [email protected] 

SOURCE ASKP3

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.